Published On: Wed, Oct 19th, 2016

Latest Analyst Reports On Ironwood Pharmaceuticals, Inc.


Recently stock market analysts have updated their consensus ratings on shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD).

Most recent broker ratings

10/10/2016 – Ironwood Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Mizuho. They now have a USD 19 price target on the stock.

09/27/2016 – Ironwood Pharmaceuticals, Inc. had its “hold” rating reiterated by analysts at WallachBeth Capital. They now have a USD 17 price target on the stock.

09/22/2016 – Ironwood Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at BTIG Research. They now have a USD 18 price target on the stock.

08/05/2016 – Ironwood Pharmaceuticals, Inc. had its “market perform” rating reiterated by analysts at Leerink Swann. They now have a USD 14 price target on the stock.

04/28/2016 – Ironwood Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at Wedbush. They now have a USD 10 price target on the stock.

04/26/2016 – Ironwood Pharmaceuticals, Inc. had its “overweight” rating reiterated by analysts at JP Morgan. They now have a USD 15 price target on the stock.

04/06/2016 – Ironwood Pharmaceuticals, Inc. was upgraded to “outperform” by analysts at Cowen. They now have a USD 16 price target on the stock.

03/21/2016 – Goldman Sachs began new coverage on Ironwood Pharmaceuticals, Inc. giving the company a “neutral” rating. They now have a USD 14 price target on the stock.

02/19/2016 – Ironwood Pharmaceuticals, Inc. had its “sell” rating reiterated by analysts at UBS. They now have a USD 8 price target on the stock.

02/19/2016 – Ironwood Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Bank of America Merrill Lynch. They now have a USD 14 price target on the stock.

02/19/2016 – Ironwood Pharmaceuticals, Inc. had its “equal-weight” rating reiterated by analysts at Barclays. They now have a USD 11 price target on the stock.

11/02/2015 – Ironwood Pharmaceuticals, Inc. had its “positive” rating reiterated by analysts at Wood & Company.

05/06/2015 – Ironwood Pharmaceuticals, Inc. was downgraded to “sell” by analysts at Zacks.

05/01/2015 – Ironwood Pharmaceuticals, Inc. had its “hold” rating reiterated by analysts at Cantor Fitzgerald. They now have a USD 13.5 price target on the stock.

07/09/2014 – Furey Research Partners began new coverage on Ironwood Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 20 price target on the stock.

Ironwood Pharmaceuticals, Inc. has a 50 day moving average of 14.78 and a 200 day moving average of 13.01. The stock’s market capitalization is 2.02B, it has a 52-week low of 7.35 and a 52-week high of 16.17.

The share price of the company (NASDAQ:IRWD) was up +0.80%, with a high of 14.17 during the day and the volume of Ironwood Pharmaceuticals, Inc. shares traded was 2408775.

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company’s products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. It operates through human therapeutics segment. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. It is engaged in developing therapeutic platforms for the treatment of vascular and fibrotic diseases, and refractory gastroesophageal reflux disease (GERD). Its IW-9179 is used for the treatment of gastroparesis and functional dyspepsia. The Company has conducted an exploratory Phase IIa clinical study of IW-3718 in patients with refractory GERD. It has two sGC development candidates, which include IW-1973 and IW-1701.